Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia
Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.
ASH 2018
ASH 2018
Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting
Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Treatment Success With HLA-Matched Donor Grafts for Beta Thalassemia From Relatives and Nonrelatives
Researchers analyzed 1110 patients who had received transplanted grafts from HLA-matched and mismatched relatives and unrelated donors.
Allogeneic Hematopoietic Cell Transplantation for Sickle Cell Disease and Thalassemia
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Infections and Immune Reconstitution With Bone Marrow Transplantation in Fanconi Anemia
Results from a study in which patients with Fanconi anemia underwent a reduced intensity conditioning regimen followed by bone marrow transplantation.
Cost of First-Line Eltrombopag to Treat Severe Aplastic Anemia
Eltrombopag plus IST was compared with IST alone in a simulated population of 1 million patients with severe aplastic anemia.
REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Reduced Need for Red Blood Cell Transfusions in Patients Treated With Luspatercept for Beta-Thalassemia
The drug’s ability to boost late-stage erythropoiesis makes it a potential treatment option for patients with beta-thalassemia.
Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
Hydroxyurea as Treatment for Children With Sickle Cell Anemia in Sub-Saharan Africa
The efficacy, safety, and feasibility of using hydroxyurea as a therapeutic agent for sickle cell anemia have not been assessed in many populations.
Secreted Mutant Calreticulins Behaving as Cytokines
Researchers probed mutant calreticulins to determine whether they were secreted and behaved extracellularly as cytokines.
Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
Stringent CR criteria may not predict clinical outcomes for patients with MM.
The Role of Salvage Autologous Transplant in the Treatment of Multiple Myeloma
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
Ibrutinib Dose Reduction Did Not Affect PFS in Waldenström Macroglobulinemia
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...